Citation: M. Oscarson, Nicotine metabolism by the polymorphic cytochrome P450 2A6 (CYP2A6) enzyme: Implications for interindividual differences in smoking behaviour target article on nicotine-addiction, PSYCOLOQUY, 12(3), 2001, pp. NIL_3-NIL_8
Authors:
Loriot, MA
Rebuissou, S
Oscarson, M
Cenee, S
Miyamoto, M
Ariyoshi, N
Kamataki, T
Hemon, D
Beaune, P
Stucker, I
Citation: Ma. Loriot et al., Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population, PHARMACOGEN, 11(1), 2001, pp. 39-44
Citation: M. Oscarson, Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: Implications for interindividual differences in nicotine metabolism, DRUG META D, 29(2), 2001, pp. 91-95
Authors:
Hidestrand, M
Oscarson, M
Salonen, JS
Nyman, L
Pelkonen, O
Turpeinen, M
Ingelman-Sundberg, M
Citation: M. Hidestrand et al., CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes, DRUG META D, 29(11), 2001, pp. 1480-1484
Authors:
Pitarque, M
von Richter, O
Oke, B
Berkkan, H
Oscarson, M
Ingelman-Sundberg, M
Citation: M. Pitarque et al., Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: Impairment of its promoter activity, BIOC BIOP R, 284(2), 2001, pp. 455-460
Authors:
Westlind, A
Malmebo, S
Johansson, I
Otter, C
Andersson, TB
Ingelman-Sundberg, M
Oscarson, M
Citation: A. Westlind et al., Cloning and tissue distribution of a novel human cytochrome P450 of the CYP3A subfamily, CYP3A43, BIOC BIOP R, 281(5), 2001, pp. 1349-1355
Authors:
Rylander, T
Neve, EPA
Ingelman-Sundberg, M
Oscarson, M
Citation: T. Rylander et al., Identification and tissue distribution of the novel human cytochrome P4502S1 (CYP2S1), BIOC BIOP R, 281(2), 2001, pp. 529-535
Authors:
Ingelman-Sundberg, M
Daly, AK
Oscarson, M
Nebert, DW
Citation: M. Ingelman-sundberg et al., Human cytochrome P450 (CYP) genes: recommendations for the nomenclature ofalleles, PHARMACOGEN, 10(1), 2000, pp. 91-93
Authors:
McLellan, RA
Oscarson, M
Hidestrand, M
Leidvik, B
Jonsson, E
Otter, C
Ingelman-Sundberg, M
Citation: Ra. Mclellan et al., Characterization and functional analysis of two common human cytochrome P4501B1 variants, ARCH BIOCH, 378(1), 2000, pp. 175-181
Authors:
Ingelman-Sundberg, M
Oscarson, M
McLellan, RA
Citation: M. Ingelman-sundberg et al., Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment, TRENDS PHAR, 20(8), 1999, pp. 342-349
Authors:
Oscarson, M
McLellan, RA
Gullsten, H
Agundez, JAG
Benitez, J
Rautio, A
Raunio, H
Pelkonen, O
Ingelman-Sundberg, M
Citation: M. Oscarson et al., Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism, FEBS LETTER, 460(2), 1999, pp. 321-327
Authors:
Oscarson, M
McLellan, RA
Gullsten, H
Yue, QY
Lang, MA
Bernal, ML
Sinues, B
Hirvonen, A
Raunio, H
Pelkonen, O
Ingelman-Sundberg, M
Citation: M. Oscarson et al., Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population, FEBS LETTER, 448(1), 1999, pp. 105-110
Authors:
Hu, Y
Hakkola, J
Oscarson, M
Ingelman-Sundberg, M
Citation: Y. Hu et al., Structural and functional characterization of the 5 '-flanking region of the rat and human cytochrome P450 2E1 genes: Identification of a polymorphicrepeat in the human gene, BIOC BIOP R, 263(2), 1999, pp. 286-293